Could This Startup Actually Disrupt The Pharmaceutical Industry?

The COVID-19 pandemic stomped on exercise as people baked banana bread and sat on the sofa. As the pandemic fades, people have become more health conscious as they try to bring that sedentary lifestyle to an end. In addition to healthier eating habits and regular exercise, people are consuming an increased variety of dietary supplements daily. 

The global dietary supplements market is expected to grow at a compound annual growth rate (CAGR) of 8.5% over the next eight years, according to a report released by Facts and Factors. 

TruBrain manufactures high-performance brain food products and nootropics designed to improve mental output, increase verbal fluency and overcome procrastination. It recently received qualification from the FDA to move forward with TruBrain’s new wearable device applications, designed to soothe the central nervous system through vibrotherapy.

Disrupting the Pharmaceutical Industry 

Though not a pharmaceutical company, TruBrain employs UCLA-trained neuroscientists to create sophisticated brain food. Most of TruBrain’s nootropics demonstrate benefits within 45 minutes of consumption on average and typically last all day. However, some customers have reported feeling the effect within 7 to 10 days as their body adjusts to the nutrients.

Since its inception in 2012, TruBrain has generated more than $18 million in lifetime sales. It has shipped more than 6 million drinks globally and has an average order value of $64. Moreover, the company has been profitable since 2019. The start-up is poised to become a leading name in the cognitive healthcare sector in the coming years. 

Trial Program for the Skeptical 

TruBrain offers a 14-day trial box for U.S.-based customers, which contains ten one-ounce shots. Following this, individuals choosing to stay enrolled receive a box of 20 of the most popular drinks every month, with the option of canceling anytime. It also allows customers to build a personalized drink box, depending on their cognitive requirements. 

Moreover, it designs the shots with seven unique patent-pending unique formulas comprising nootropics, minerals, hemp and functional oils. 

Prominent Investor Backing 

TruBrain has raised over $3.8 million from high-profile venture capitalists including 500 Startups and Sherpa Venture Capita. Apart from this, the platform raised $1.7 million in previous Regulation A+ and crowdfunding rounds. It currently has more than 2,000 social investors. 

Crowdfunding Investment Opportunity 

TruBrain’s latest crowdfunding round has raised over $1 million from retail investors so far. The start-up currently has a $24.3 million enterprise valuation. Investors can gain a stake in TruBrain for 43 cents per share through its latest equity crowdfunding round on StartEngine. 

With an international customer base across eight countries, TruBrain is poised to carve out a strong foothold in the $38 billion personalized healthcare market.